ME02473B - Heterociklična jedinjenja i njihova primjena - Google Patents
Heterociklična jedinjenja i njihova primjenaInfo
- Publication number
- ME02473B ME02473B MEP-2016-61A MEP201661A ME02473B ME 02473 B ME02473 B ME 02473B ME P201661 A MEP201661 A ME P201661A ME 02473 B ME02473 B ME 02473B
- Authority
- ME
- Montenegro
- Prior art keywords
- inflammatory
- compound according
- pharmaceutically acceptable
- disorders
- rheumatoid arthritis
- Prior art date
Links
- 150000002391 heterocyclic compounds Chemical class 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 21
- 208000023275 Autoimmune disease Diseases 0.000 claims 14
- 208000035475 disorder Diseases 0.000 claims 14
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 14
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 14
- 150000003839 salts Chemical class 0.000 claims 8
- 206010027654 Allergic conditions Diseases 0.000 claims 7
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 7
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 7
- 206010020751 Hypersensitivity Diseases 0.000 claims 7
- 206010020853 Hypertonic bladder Diseases 0.000 claims 7
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 7
- 201000004681 Psoriasis Diseases 0.000 claims 7
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 7
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 7
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 7
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 7
- 208000002552 acute disseminated encephalomyelitis Diseases 0.000 claims 7
- 208000026935 allergic disease Diseases 0.000 claims 7
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 7
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 7
- 230000001684 chronic effect Effects 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 7
- 208000030533 eye disease Diseases 0.000 claims 7
- 230000009610 hypersensitivity Effects 0.000 claims 7
- 230000004968 inflammatory condition Effects 0.000 claims 7
- 208000027866 inflammatory disease Diseases 0.000 claims 7
- 201000006417 multiple sclerosis Diseases 0.000 claims 7
- 206010028417 myasthenia gravis Diseases 0.000 claims 7
- 201000008482 osteoarthritis Diseases 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 7
- 239000000546 pharmaceutical excipient Substances 0.000 claims 7
- 230000005808 skin problem Effects 0.000 claims 7
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (22)
1. Jedinjenje odabrano izmeđui ili bilo koja njegova farmaceutski prihvatljiva so.
2. Jedinjenje prema zahtevu 1 koje ima strukturu ili bilo koja njegova farmaceutski prihvatljiva so.
3. Jedinjenje prema zahtevu 1 koje ima strukturu ili bilo koja njegova farmaceutski prihvatljiva so.
4. Jedinjenje prema zahtevu 1 koje ima strukturu ili bilo koja njegova farmaceutski prihvatljiva so.
5. Jedinjenje prema zahtevu 1 koje ima strukturu ili bilo koja njegova farmaceutski prihvatljiva so.
6. Jedinjenje prema zahtevu 1 koje ima strukturu ili bilo koja njegova farmaceutski prihvatljiva so.
7. Jedinjenje prema zahtevu 1 koje ima strukturu ili bilo koja njegova farmaceutski prihvatljiva so.
8. Jedinjenje prema zahtevu 1 koje ima strukturu ili bilo koja njegova farmaceutski prihvatljiva so. Top of Form
9. Farmaceutska kompozicija koja obuhvata terapeutski efikasnu količinu jedinjenja prema zahtevu 2, i farmaceutski prihvatljiv ekscipijens ili nosač.
10. Farmaceutska kompozicija koja obuhvata terapeutski efikasnu količinu jedinjenja prema zahtevu 3, i farmaceutski prihvatljiv ekscipijens ili nosač.
11. Farmaceutska kompozicija koja obuhvata terapeutski efikasnu količinu jedinjenja prema zahtevu 4, i farmaceutski prihvatljiv ekscipijens ili nosač.
12. Farmaceutska kompozicija koja obuhvata terapeutski efikasnu količinu jedinjenja prema zahtevu 5, i farmaceutski prihvatljiv ekscipijens ili nosač.
13. Farmaceutska kompozicija koja obuhvata terapeutski efikasnu količinu jedinjenja prema zahtevu 6, i farmaceutski prihvatljiv ekscipijens ili nosač.
14. Farmaceutska kompozicija koja obuhvata terapeutski efikasnu količinu jedinjenja prema zahtevu 7, i farmaceutski prihvatljiv ekscipijens ili nosač.
15. Farmaceutska kompozicija koja obuhvata terapeutski efikasnu količinu jedinjenja prema zahtevu 8, i farmaceutski prihvatljiv ekscipijens ili nosač.
16. Jedinjenje prema zahtevu 2 za upotrebu u tretiranju bolesti odabrane između reumatoidnog artritisa, ankilozirajućeg spondilitisa, osteoartritisa, psorijaznog artritisa, psorijaze, zapaljenskih bolesti i autoimunih bolesti, zapaljenskih poremećaja creva, zapaljenskih poremećaja oka, zapaljenskih ili poremećaja nestabilne bešike, kožnih problema sa zapaljenskim komponentama, hroničnih zapaljenskih stanja, autoimunih bolesti, sistemskog eritemskog lupusa (SLE), mistenije gravis, reumatoidninog artritisa, akutnog diseminiranog encefalomijelitisa, idiopatske trombocitopenične purpure, multiple skleroze, Sjoegrenovog sindroma i autoimune hemolitičke anemije, alergijskih stanja i preosetljivosti.
17. Jedinjenje prema zahtevu 3 za upotrebu u tretiranju bolesti odabrane između reumatoidnog artritisa, ankilozirajućeg spondilitisa, osteoartritisa, psorijaznog artritisa, psorijaze, zapaljenskih bolesti i autoimunih bolesti, zapaljenskih poremećaja creva, zapaljenskih poremećaja oka, zapaljenskih ili poremećaja nestabilne bešike, kožnih problema sa zapaljenskim komponentama, hroničnih zapaljenskih stanja, autoimunih bolesti, sistemskog eritemskog lupusa (SLE), mistenije gravis, reumatoidninog artritisa, akutnog diseminiranog encefalomijelitisa, idiopatske trombocitopenične purpure, multiple skleroze, Sjoegrenovog sindroma i autoimune hemolitičke anemije, alergijskih stanja i preosetljivosti.
18. Jedinjenje prema zahtevu 4 za upotrebu u tretiranju bolesti odabrane između reumatoidnog artritisa, ankilozirajućeg spondilitisa, osteoartritisa, psorijaznog artritisa, psorijaze, zapaljenskih bolesti i autoimunih bolesti, zapaljenskih poremećaja creva, zapaljenskih poremećaja oka, zapaljenskih ili poremećaja nestabilne bešike, kožnih problema sa zapaljenskim komponentama, hroničnih zapaljenskih stanja, autoimunih bolesti, sistemskog eritemskog lupusa (SLE), mistenije gravis, reumatoidninog artritisa, akutnog diseminiranog encefalomijelitisa, idiopatske trombocitopenične purpure, multiple skleroze, Sjoegrenovog sindroma i autoimune hemolitičke anemije, alergijskih stanja i preosetljivosti.
19. Jedinjenje prema zahtevu 5 za upotrebu u tretiranju bolesti odabrane između reumatoidnog artritisa, ankilozirajućeg spondilitisa, osteoartritisa, psorijaznog artritisa, psorijaze, zapaljenskih bolesti i autoimunih bolesti, zapaljenskih poremećaja creva, zapaljenskih poremećaja oka, zapaljenskih ili poremećaja nestabilne bešike, kožnih problema sa zapaljenskim komponentama, hroničnih zapaljenskih stanja, autoimunih bolesti, sistemskog eritemskog lupusa (SLE), mistenije gravis, reumatoidninog artritisa, akutnog diseminiranog encefalomijelitisa, idiopatske trombocitopenične purpure, multiple skleroze, Sjoegrenovog sindroma i autoimune hemolitičke anemije, alergijskih stanja i preosetljivosti.
20. Jedinjenje prema zahtevu 6 za upotrebu u tretiranju bolesti odabrane između reumatoidnog artritisa, ankilozirajućeg spondilitisa, osteoartritisa, psorijaznog artritisa, psorijaze, zapaljenskih bolesti i autoimunih bolesti, zapaljenskih poremećaja creva, zapaljenskih poremećaja oka, zapaljenskih ili poremećaja nestabilne bešike, kožnih problema sa zapaljenskim komponentama, hroničnih zapaljenskih stanja, autoimunih bolesti, sistemskog eritemskog lupusa (SLE), mistenije gravis, reumatoidninog artritisa, akutnog diseminiranog encefalomijelitisa, idiopatske trombocitopenične purpure, multiple skleroze, Sjoegrenovog sindroma i autoimune hemolitičke anemije, alergijskih stanja i preosetljivosti.
21. Jedinjenje prema zahtevu 7 za upotrebu u tretiranju bolesti odabrane između reumatoidnog artritisa, ankilozirajućeg spondilitisa, osteoartritisa, psorijaznog artritisa, psorijaze, zapaljenskih bolesti i autoimunih bolesti, zapaljenskih poremećaja creva, zapaljenskih poremećaja oka, zapaljenskih ili poremećaja nestabilne bešike, kožnih problema sa zapaljenskim komponentama, hroničnih zapaljenskih stanja, autoimunih bolesti, sistemskog eritemskog lupusa (SLE), mistenije gravis, reumatoidninog artritisa, akutnog diseminiranog encefalomijelitisa, idiopatske trombocitopenične purpure, multiple skleroze, Sjoegrenovog sindroma i autoimune hemolitičke anemije, alergijskih stanja i preosetljivosti.
22. Jedinjenje prema zahtevu 8 za upotrebu u tretiranju bolesti odabrane između reumatoidnog artritisa, ankilozirajućeg spondilitisa, osteoartritisa, psorijaznog artritisa, psorijaze, zapaljenskih bolesti i autoimunih bolesti, zapaljenskih poremećaja creva, zapaljenskih poremećaja oka, zapaljenskih ili poremećaja nestabilne bešike, kožnih problema sa zapaljenskim komponentama, hroničnih zapaljenskih stanja, autoimunih bolesti, sistemskog eritemskog lupusa (SLE), mistenije gravis, reumatoidninog artritisa, akutnog diseminiranog encefalomijelitisa, idiopatske trombocitopenične purpure, multiple skleroze, Sjoegrenovog sindroma i autoimune hemolitičke anemije, alergijskih stanja i preosetljivosti.Bottom of Form
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261620270P | 2012-04-04 | 2012-04-04 | |
| EP13717655.8A EP2834231B1 (en) | 2012-04-04 | 2013-04-04 | Heterocyclic compounds and their uses |
| PCT/US2013/035203 WO2013152150A1 (en) | 2012-04-04 | 2013-04-04 | Heterocyclic compounds and their uses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02473B true ME02473B (me) | 2017-02-20 |
Family
ID=48142975
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2016-61A ME02473B (me) | 2012-04-04 | 2013-04-04 | Heterociklična jedinjenja i njihova primjena |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US8716290B2 (me) |
| EP (1) | EP2834231B1 (me) |
| JP (1) | JP2015512451A (me) |
| KR (1) | KR20140139547A (me) |
| CN (1) | CN104395305A (me) |
| AP (1) | AP3611A (me) |
| AU (1) | AU2013243506A1 (me) |
| CA (1) | CA2869413A1 (me) |
| CL (1) | CL2014002686A1 (me) |
| CO (1) | CO7091181A2 (me) |
| CR (1) | CR20140503A (me) |
| CY (1) | CY1117487T1 (me) |
| DK (1) | DK2834231T3 (me) |
| EA (1) | EA201491823A1 (me) |
| ES (1) | ES2577109T3 (me) |
| HR (1) | HRP20160352T1 (me) |
| HU (1) | HUE028762T2 (me) |
| IL (1) | IL234822A0 (me) |
| MA (1) | MA37472A1 (me) |
| ME (1) | ME02473B (me) |
| MX (1) | MX2014011970A (me) |
| PE (1) | PE20142457A1 (me) |
| PH (1) | PH12014502246A1 (me) |
| PL (1) | PL2834231T3 (me) |
| RS (1) | RS54716B1 (me) |
| SG (1) | SG11201406316VA (me) |
| SI (1) | SI2834231T1 (me) |
| SM (1) | SMT201600211B (me) |
| TN (1) | TN2014000412A1 (me) |
| WO (1) | WO2013152150A1 (me) |
| ZA (1) | ZA201407037B (me) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2011329806A1 (en) * | 2010-11-17 | 2013-05-30 | Amgen Inc. | Quinoline derivatives as PIK3 inhibitors |
| AU2013243506A1 (en) * | 2012-04-04 | 2014-10-09 | Amgen Inc. | Heterocyclic compounds and their uses |
| WO2015171725A1 (en) | 2014-05-06 | 2015-11-12 | Amgen Inc. | Hydrate, crystalline hydrate and crystalline anhydrate forms of n-((1s)-1-(7-fluoro-2-(2-pyridinyl)-3-quinolinyl)ethyl)-9h-purin-6-amine, pharmaceutical compositions containing them and methods for treating cancer. |
| UA115296C2 (uk) | 2014-07-04 | 2017-10-10 | Люпін Лімітед | Хінолізинонові похідні як інгібітори pi3k |
| US9637488B2 (en) | 2015-01-29 | 2017-05-02 | Fuqiang Ruan | Heterocyclic compounds as inhibitors of class I PI3KS |
| US10792283B2 (en) * | 2016-03-05 | 2020-10-06 | Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. | Quinoline analogs as phosphatidylinositol 3-kinase inhibitors |
| TW201825465A (zh) | 2016-09-23 | 2018-07-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201815787A (zh) | 2016-09-23 | 2018-05-01 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TW201813963A (zh) | 2016-09-23 | 2018-04-16 | 美商基利科學股份有限公司 | 磷脂醯肌醇3-激酶抑制劑 |
| TWI853009B (zh) * | 2019-03-29 | 2024-08-21 | 瑞士商先正達農作物保護公司 | 殺有害生物活性之二-醯胺化合物 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72878B (en) | 1980-04-24 | 1983-03-29 | Merck & Co Inc | Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents |
| US6043062A (en) | 1995-02-17 | 2000-03-28 | The Regents Of The University Of California | Constitutively active phosphatidylinositol 3-kinase and uses thereof |
| GB9611460D0 (en) | 1996-06-01 | 1996-08-07 | Ludwig Inst Cancer Res | Novel lipid kinase |
| US5858753A (en) | 1996-11-25 | 1999-01-12 | Icos Corporation | Lipid kinase |
| US5822910A (en) | 1997-10-02 | 1998-10-20 | Shewmake; I. W. | Fishing line tensioning device |
| JP5065017B2 (ja) * | 2004-06-28 | 2012-10-31 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | ４，６位で二置換されたピリミジン及びプロテインキナーゼインヒビターとしてのそれらの使用 |
| MX2009010050A (es) * | 2007-03-23 | 2009-10-12 | Amgen Inc | Derivados de quinolina o quinoxalina 3-sustituidos y su uso como inhibidores de fosfotidilinositol 3-cinasa (p13k). |
| WO2009081105A2 (en) * | 2007-12-21 | 2009-07-02 | Ucb Pharma S.A. | Quinoxaline and quinoline derivatives as kinase inhibitors |
| EP2365810A2 (en) * | 2008-12-04 | 2011-09-21 | The U.S.A. As Represented By The Secretary, Department Of Health And Human Services | Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders |
| UY32743A (es) * | 2009-06-25 | 2010-12-31 | Amgen Inc | Compuestos heterocíclicos y sus usos |
| EP2513109A1 (en) * | 2009-12-18 | 2012-10-24 | Amgen Inc. | Heterocyclic compounds and their uses |
| US20130096134A1 (en) * | 2010-07-02 | 2013-04-18 | Amgen Inc. | Heterocyclic compounds and their uses |
| AU2013243506A1 (en) * | 2012-04-04 | 2014-10-09 | Amgen Inc. | Heterocyclic compounds and their uses |
-
2013
- 2013-04-04 AU AU2013243506A patent/AU2013243506A1/en not_active Abandoned
- 2013-04-04 SG SG11201406316VA patent/SG11201406316VA/en unknown
- 2013-04-04 PE PE2014001529A patent/PE20142457A1/es not_active Application Discontinuation
- 2013-04-04 CN CN201380017551.2A patent/CN104395305A/zh active Pending
- 2013-04-04 DK DK13717655.8T patent/DK2834231T3/en active
- 2013-04-04 EP EP13717655.8A patent/EP2834231B1/en active Active
- 2013-04-04 CA CA2869413A patent/CA2869413A1/en not_active Abandoned
- 2013-04-04 ME MEP-2016-61A patent/ME02473B/me unknown
- 2013-04-04 MA MA37472A patent/MA37472A1/fr unknown
- 2013-04-04 RS RS20160272A patent/RS54716B1/sr unknown
- 2013-04-04 ES ES13717655.8T patent/ES2577109T3/es active Active
- 2013-04-04 KR KR1020147028346A patent/KR20140139547A/ko not_active Withdrawn
- 2013-04-04 HR HRP20160352TT patent/HRP20160352T1/hr unknown
- 2013-04-04 EA EA201491823A patent/EA201491823A1/ru unknown
- 2013-04-04 PL PL13717655T patent/PL2834231T3/pl unknown
- 2013-04-04 JP JP2015504713A patent/JP2015512451A/ja not_active Ceased
- 2013-04-04 US US13/856,500 patent/US8716290B2/en active Active
- 2013-04-04 AP AP2014007979A patent/AP3611A/xx active
- 2013-04-04 SI SI201330170A patent/SI2834231T1/sl unknown
- 2013-04-04 WO PCT/US2013/035203 patent/WO2013152150A1/en not_active Ceased
- 2013-04-04 MX MX2014011970A patent/MX2014011970A/es unknown
- 2013-04-04 HU HUE13717655A patent/HUE028762T2/en unknown
-
2014
- 2014-03-21 US US14/221,499 patent/US8835432B2/en active Active
- 2014-09-23 IL IL234822A patent/IL234822A0/en unknown
- 2014-09-26 ZA ZA2014/07037A patent/ZA201407037B/en unknown
- 2014-09-30 TN TNP2014000412A patent/TN2014000412A1/fr unknown
- 2014-10-03 PH PH12014502246A patent/PH12014502246A1/en unknown
- 2014-10-03 CL CL2014002686A patent/CL2014002686A1/es unknown
- 2014-10-07 CO CO14222148A patent/CO7091181A2/es unknown
- 2014-10-30 CR CR20140503A patent/CR20140503A/es unknown
-
2016
- 2016-04-26 CY CY20161100347T patent/CY1117487T1/el unknown
- 2016-07-05 SM SM201600211T patent/SMT201600211B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ME02473B (me) | Heterociklična jedinjenja i njihova primjena | |
| HRP20171076T1 (hr) | Derivati piridazinon-amida | |
| JP2013533884A5 (me) | ||
| EA201892790A1 (ru) | Применение 2-замещенных индазолов для лечения и профилактики аутоиммунных заболеваний | |
| HRP20191430T1 (hr) | Spojevi heteroarila kao inhibitori btk i njihove uporabe | |
| HRP20210252T1 (hr) | Heterociklički amidi kao inhibitori kinaze | |
| WO2013171729A3 (en) | Aryl and heteroaryl amide compounds as ror gamma t modulator | |
| ME01916B (me) | Novi spoj koristan u liječenju degenerativnih upalnih bolesti | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| EP3669246A4 (en) | DETECTING THE MOVEMENT OF AN AUTONOMOUS VEHICLE USING RADAR TECHNOLOGY | |
| HRP20210472T1 (hr) | Biciklički kondenzirani heteroarilni ili arilni spojevi kao modulatori irak4 | |
| CL2015001231A1 (es) | Compuestos heterocíclicos sustituidos con amida; composicion farmaceutica; útiles en el tratamiento de una enfermedad inflamatoria o autoinmune. | |
| EP3022560A4 (en) | BLOOD-BASED SCREEN FOR DETECTION OF NEUROLOGICAL DISEASES IN MEDICAL PRIMARY ENVIRONMENTAL ENVIRONMENTS | |
| JP2013530236A5 (me) | ||
| EP3381438A4 (en) | COMPOSITION FOR INJECTION OF HYALURONIC ACID WITH HYALURONIC ACID DERIVATIVE AND DNA FRACTION AND USE THEREOF | |
| HRP20241145T1 (hr) | Biciklički aza spojevi kao agonisti muskarinskih receptora | |
| WO2013048214A3 (en) | Novel heterocyclic derivatives and their uses | |
| TN2012000061A1 (en) | (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)-amide tablet formulations with improved stability | |
| JP2016506386A5 (me) | ||
| HRP20221098T1 (hr) | Tretman kognitivnih i simptoma poremećaja raspoloženja kod neurodegenerativnih i neuropsihijatrijskih poremećaja agonistima gabaa receptora koji sadrže alfa5 | |
| CL2014000007A1 (es) | Compuestos derivados de oxazol y tiazol, inhibidores selectivos de proteinas quinasas; composicion farmaceutica; combinacion farmaceutica; su uso en el tratamiento de enfermedades tales como mastocitosis, neoplasia hematologica, trastorno mieloproliferativo, enfermedad autoinmune, enfermedad inflamatoria, alergias o enfermedad neurologica. | |
| EP3600263A4 (en) | MICROCELL SYSTEMS FOR THE DELIVERY OF ACTIVE MOLECULES | |
| FR3003171B1 (fr) | Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire | |
| EP3414826A4 (en) | ELECTRONIC PLUG-AND-PLAY CONDENSER FOR VOLTAGE REGULATOR MODULES | |
| EP3369774A4 (en) | LIQUID CRYSTALLINE POLYESTER RESIN COMPOSITION FOR USE WITH CAMERA MODULES AND PRODUCT FORMED THEREFOR FOR USE WITH CAMERA MODULES |